Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,118 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
New DistributeRx partnership with Resilia Pharmaceuticals 2 pages 161.7KB
Regulatory Filings Classification · 85% confidence The document is an ASX announcement detailing a commercial distribution partnership between Mayne Pharma’s subsidiary and Resilia Pharmaceuticals. It provides no financial results, no AGM materials, no management or board changes, no capital/fundraising activity, dividends, share issues, or other specific categories. It is a routine regulatory announcement (press release) filed with the exchange that does not fit the specialized categories, so it falls under the general Regulatory Filings (RNS) category.
2026-06-01 English
Mayne Pharma to present at Jefferies Healthcare Conference 1 page 113.4KB
Report Publication Announcement Classification · 75% confidence The document is a brief ASX announcement about an upcoming investor presentation at a conference and notes that “a copy of the presentation will be lodged to ASX” prior to the event. It does not contain the presentation itself or substantive financial data; instead it simply notifies investors of the forthcoming release of a presentation. Under the “menu vs. meal” rule for distinguishing announcements of report/publication from the report itself, this is a report publication announcement (RPA).
2026-05-26 English
Court awards MYX $13.27m for legal costs from Cosette 2 pages 162.3KB
Legal Proceedings Report Classification · 92% confidence The document is a public ASX announcement detailing the outcome of legal proceedings in which Mayne Pharma was awarded legal costs by the Supreme Court. It provides an update on a significant lawsuit and court judgment, with no financial report data or meeting details. This fits squarely into the Legal Proceedings Report category.
2026-05-21 English
Mayne Pharma announces expansion of Adelaide Apothecary 3 pages 217.4KB
Regulatory Filings Classification · 87% confidence The document is an ASX announcement providing general business news about a new leased facility and associated capital expenditure for Mayne Pharma’s specialty pharmacy subsidiary. It does not represent a financial report, fundraising/financing terms, dividends, or an operational earnings release. It is not raising equity or debt but simply discloses strategic asset expansion and capex projections. As such it falls into the fallback “Regulatory Filings” category for miscellaneous ASX regulatory disclosures that do not fit other specific categories.
2026-05-17 English
Mayne Pharma 3Q investor presentation 24 pages 1.2MB
Investor Presentation Classification · 100% confidence The document is titled 'MAYNE PHARMA 3Q INVESTOR PRESENTATION' and dated 7 May 2026. It provides a detailed overview of the company's third quarter financial results for fiscal year 2026, including revenue, EBITDA, segment performance, and strategic initiatives. The content includes financial metrics, operational highlights, segment analysis, and forward-looking statements typical of an investor presentation. The document is about 15,000 characters long, indicating it is a full presentation rather than a brief announcement. It explicitly states it is an 'Investor Presentation' and includes detailed financial and strategic information aimed at investors. Therefore, the document fits the category of an Investor Presentation (IP).
2026-05-06 English
Notification of cessation of securities - MYX 4 pages 14.9KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of performance rights (unquoted equity securities) for Mayne Pharma Group Limited. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. This type of announcement is a regulatory filing notifying the market and ASX about changes in the company's securities, specifically cessation of securities. It is not a financial report, earnings release, or management discussion. The document length is 3498 characters, which is relatively short and focused on a specific securities cessation event. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about securities changes that does not fit other more specific categories like Share Issue/Capital Change (SHA) or Director's Dealing (DIRS).
2026-05-03 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.